Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients

Recruiting now

Conditions studied: Multiple Myeloma

In brief

This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy. A minimum of 159 patients is required. Overall study duration is estimated in 36 months.

Key facts

Study ID

NCT06933277

Run by

Gruppo Italiano Malattie EMatologiche dell'Adulto

People needed

159

Starts

2025-08-29

Expected to finish

2028-08-01

Last updated by the study team

2025-09-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age equal to or greater than 18 years old at the time of SVd initiation
• Signed informed consent (if applicable).
• Diagnosis of symptomatic MM, as defined by the International Myeloma Working Group (IMWG) criteria.
• Relapse after one to three lines of therapy.
• Treatment with SVd, (i.e., having already received at least one dose) at the time the combination has entered clinical practice in Italy (AIFA authorization)
• Prior treatment with and refractoriness to lenalidomide.

You may not qualify if…

• Previous exposure to selinexor.

Where it is running

• Aou Careggi - Sod Ematologia — Florence, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.